b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="In-Process" Owner="NLM">\n        <PMID Version="1">32139179</PMID>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>04</Month>\n            <Day>08</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">2352-3964</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>53</Volume>\n                    <PubDate>\n                        <Year>2020</Year>\n                        <Month>Mar</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>EBioMedicine</Title>\n                <ISOAbbreviation>EBioMedicine</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Recent insights into the biology of pancreatic cancer.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>102655</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="pii" ValidYN="Y">S2352-3964(20)30030-X</ELocationID>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ebiom.2020.102655</ELocationID>\n            <Abstract>\n                <AbstractText>Pancreatic cancer (PDAC) is one of the deadliest types of human cancers, owing to late stage at presentation and pervasive therapeutic resistance. The extensive tumour heterogeneity, as well as substantial crosstalk between the neoplastic epithelium and components within the microenvironment are the defining features of PDAC biology that dictate the dismal natural history. Recent advances in genomic and molecular profiling have informed on the genetic makeup and evolutionary patterns of tumour progression, leading to treatment breakthroughs in minor subsets of patients with specific tumour mutational profiles. The nature and function of tumour heterogeneity, including stromal heterogeneity, in PDAC development and therapeutic resistance, are increasingly being elucidated. Deep insight has been gained regarding the metabolic and immunological deregulation, which further sheds light on the complex biology and the observed treatment recalcitrance. Here we will summarize these recent achievements and offer our perspective on the path forward.</AbstractText>\n                <CopyrightInformation>Copyright \xc2\xa9 2020 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Yao</LastName>\n                    <ForeName>Wantong</ForeName>\n                    <Initials>W</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Translational Molecular Pathology, Houston, TX, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Maitra</LastName>\n                    <ForeName>Anirban</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Translational Molecular Pathology, Houston, TX, USA; Sheikh Ahmed Center for Pancreatic Cancer Research, Houston, TX, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Ying</LastName>\n                    <ForeName>Haoqiang</ForeName>\n                    <Initials>H</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: hying@mdanderson.org.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D016454">Review</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2020</Year>\n                <Month>03</Month>\n                <Day>02</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>Netherlands</Country>\n            <MedlineTA>EBioMedicine</MedlineTA>\n            <NlmUniqueID>101647039</NlmUniqueID>\n            <ISSNLinking>2352-3964</ISSNLinking>\n        </MedlineJournalInfo>\n        <CitationSubset>IM</CitationSubset>\n        <CommentsCorrectionsList>\n            <CommentsCorrections RefType="CommentIn">\n                <RefSource>Lancet Oncol. 2020 Mar;21(3):334-335</RefSource>\n                <PMID Version="1">32135099</PMID>\n            </CommentsCorrections>\n        </CommentsCorrectionsList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">Cancer metabolism</Keyword>\n            <Keyword MajorTopicYN="N">Evasion</Keyword>\n            <Keyword MajorTopicYN="N">Genetics</Keyword>\n            <Keyword MajorTopicYN="N">Immune</Keyword>\n            <Keyword MajorTopicYN="N">Immunotherapy</Keyword>\n            <Keyword MajorTopicYN="N">Pancreatic cancer</Keyword>\n            <Keyword MajorTopicYN="N">Ttumour heterogeneity</Keyword>\n        </KeywordList>\n        <CoiStatement>Declaration of competing interest The authors claim no conflict of interest.</CoiStatement>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2019</Year>\n                <Month>11</Month>\n                <Day>09</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="revised">\n                <Year>2019</Year>\n                <Month>12</Month>\n                <Day>16</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2020</Year>\n                <Month>01</Month>\n                <Day>21</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2020</Year>\n                <Month>3</Month>\n                <Day>7</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2020</Year>\n                <Month>3</Month>\n                <Day>7</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2020</Year>\n                <Month>3</Month>\n                <Day>7</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">32139179</ArticleId>\n            <ArticleId IdType="pii">S2352-3964(20)30030-X</ArticleId>\n            <ArticleId IdType="doi">10.1016/j.ebiom.2020.102655</ArticleId>\n            <ArticleId IdType="pmc">PMC7118569</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'